Media coverage about Penumbra (NYSE:PEN) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Penumbra earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.3351385472506 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
A number of analysts recently commented on the stock. Goldman Sachs Group assumed coverage on shares of Penumbra in a research report on Wednesday, April 4th. They issued a “buy” rating and a $145.00 price objective for the company. Canaccord Genuity restated a “buy” rating and issued a $125.00 price objective on shares of Penumbra in a research report on Thursday, April 5th. Zacks Investment Research cut shares of Penumbra from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 12th. BMO Capital Markets upped their price objective on shares of Penumbra from $115.00 to $140.00 and gave the company a “market perform” rating in a research report on Wednesday, May 9th. Finally, ValuEngine upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a research report on Wednesday, May 9th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $161.20.
Shares of PEN traded down $1.55 during trading hours on Thursday, reaching $141.15. The stock had a trading volume of 6,852 shares, compared to its average volume of 510,328. The stock has a market cap of $4.89 billion, a P/E ratio of -14,115.00, a P/E/G ratio of 43.24 and a beta of 0.17. Penumbra has a 52 week low of $77.75 and a 52 week high of $167.35.
Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, May 8th. The company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.08. The firm had revenue of $102.70 million during the quarter, compared to analyst estimates of $90.98 million. Penumbra had a net margin of 3.65% and a return on equity of 1.13%. The company’s revenue for the quarter was up 40.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) EPS. research analysts predict that Penumbra will post 0.17 earnings per share for the current year.
In related news, EVP Robert D. Evans sold 5,000 shares of the company’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $125.69, for a total value of $628,450.00. Following the completion of the transaction, the executive vice president now directly owns 17,225 shares of the company’s stock, valued at approximately $2,165,010.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Lynn Rothman sold 4,900 shares of the company’s stock in a transaction on Friday, May 4th. The stock was sold at an average price of $135.04, for a total transaction of $661,696.00. Following the completion of the transaction, the executive vice president now directly owns 139,419 shares of the company’s stock, valued at $18,827,141.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,900 shares of company stock valued at $3,002,726. Company insiders own 10.70% of the company’s stock.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.